Artivion, Inc. Just Reported A Surprise Loss: Here's What Analysts Think Will Happen Next

It's been a sad week for Artivion, Inc. (NYSE:AORT), who've watched their investment drop 13% to US$25.42 in the week since the company reported its full-year result. Things were not great overall, with a surprise (statutory) loss of US$0.32 per share on revenues of US$389m, even though the analysts had been expecting a profit. Following the result, the analysts have updated their earnings model, and it would be good to know whether they think there's been a strong change in the company's prospects, or if it's business as usual. With this in mind, we've gathered the latest statutory forecasts to see what the analysts are expecting for next year.

Check out our latest analysis for Artivion

earnings-and-revenue-growth
NYSE:AORT Earnings and Revenue Growth February 27th 2025

Taking into account the latest results, the most recent consensus for Artivion from five analysts is for revenues of US$423.4m in 2025. If met, it would imply a notable 9.0% increase on its revenue over the past 12 months. Earnings are expected to improve, with Artivion forecast to report a statutory profit of US$0.14 per share. Yet prior to the latest earnings, the analysts had been anticipated revenues of US$430.2m and earnings per share (EPS) of US$0.14 in 2025. So it's pretty clear that, although the analysts have updated their estimates, there's been no major change in expectations for the business following the latest results.

It will come as no surprise then, to learn that the consensus price target is largely unchanged at US$32.80. There's another way to think about price targets though, and that's to look at the range of price targets put forward by analysts, because a wide range of estimates could suggest a diverse view on possible outcomes for the business. There are some variant perceptions on Artivion, with the most bullish analyst valuing it at US$35.00 and the most bearish at US$32.00 per share. This is a very narrow spread of estimates, implying either that Artivion is an easy company to value, or - more likely - the analysts are relying heavily on some key assumptions.

Of course, another way to look at these forecasts is to place them into context against the industry itself. The period to the end of 2025 brings more of the same, according to the analysts, with revenue forecast to display 9.0% growth on an annualised basis. That is in line with its 8.7% annual growth over the past five years. Compare this with the broader industry, which analyst estimates (in aggregate) suggest will see revenues grow 7.8% annually. So although Artivion is expected to maintain its revenue growth rate, it's only growing at about the rate of the wider industry.

Advertisement

The Bottom Line

The most important thing to take away is that there's been no major change in sentiment, with the analysts reconfirming that the business is performing in line with their previous earnings per share estimates. Happily, there were no real changes to revenue forecasts, with the business still expected to grow in line with the overall industry. There was no real change to the consensus price target, suggesting that the intrinsic value of the business has not undergone any major changes with the latest estimates.

Keeping that in mind, we still think that the longer term trajectory of the business is much more important for investors to consider. At Simply Wall St, we have a full range of analyst estimates for Artivion going out to 2027, and you can see them free on our platform here..

It is also worth noting that we have found 1 warning sign for Artivion that you need to take into consideration.

New: Manage All Your Stock Portfolios in One Place

We've created the ultimate portfolio companion for stock investors, and it's free.

• Connect an unlimited number of Portfolios and see your total in one currency
• Be alerted to new Warning Signs or Risks via email or mobile
• Track the Fair Value of your stocks

Try a Demo Portfolio for Free

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

About NYSE:AORT

Artivion

Manufactures, processes, and distributes medical devices and implantable human tissues worldwide.

Reasonable growth potential with adequate balance sheet.

Advertisement

Weekly Picks

TA
Talos
TSLA logo
Talos on Tesla ·

The "Physical AI" Monopoly – A New Industrial Revolution

Fair Value:US$665.3637.3% undervalued
32 users have followed this narrative
14 users have commented on this narrative
18 users have liked this narrative
MA
CSG logo
Marek_Trnka on CSG ·

Czechoslovak Group - is it really so hot?

Fair Value:€5548.6% undervalued
37 users have followed this narrative
1 users have commented on this narrative
13 users have liked this narrative
AL
alex30free
SECARE logo
alex30free on Swedencare ·

The Compound Effect: From Acquisition to Integration

Fair Value:SEK 46.2846.8% undervalued
10 users have followed this narrative
0 users have commented on this narrative
1 users have liked this narrative

Updated Narratives

RE
PROX logo
RecMag on Proximus ·

Proximus: The State-Backed Backup Plan with 7% Gross Yield and 15% Currency Upside.

Fair Value:€2566.5% undervalued
37 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative
RO
RockeTeller
RYO logo
RockeTeller on Rio Silver ·

Rare Pure High Grade Silver with 35% Insider (Near Producer)

Fair Value:CA$2297.1% undervalued
1 users have followed this narrative
1 users have commented on this narrative
0 users have liked this narrative
AL
alex30free
VIT B logo
alex30free on Vitec Software Group ·

Swedens Constellation Software

Fair Value:SEK 316.8923.3% undervalued
1 users have followed this narrative
0 users have commented on this narrative
0 users have liked this narrative

Popular Narratives

DA
davidlsander
UBI logo
davidlsander on Ubisoft Entertainment ·

Is Ubisoft the Market’s Biggest Pricing Error? Why Forensic Value Points to €33 Per Share

Fair Value:€33.886.3% undervalued
57 users have followed this narrative
5 users have commented on this narrative
25 users have liked this narrative
AN
AnalystConsensusTarget
NVDA logo
AnalystConsensusTarget on NVIDIA ·

NVDA: Expanding AI Demand Will Drive Major Data Center Investments Through 2026

Fair Value:US$253.0227.7% undervalued
1068 users have followed this narrative
6 users have commented on this narrative
32 users have liked this narrative
AN
AnalystConsensusTarget
MSFT logo
AnalystConsensusTarget on Microsoft ·

Analyst Commentary Highlights Microsoft AI Momentum and Upward Valuation Amid Growth and Competitive Risks

Fair Value:US$603.2233.5% undervalued
1272 users have followed this narrative
2 users have commented on this narrative
9 users have liked this narrative

Trending Discussion

Advertisement